Ocuphire Pharma, Inc.

Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents

Read Press Release

Clinical Trials

Current Trials

Enrolling

Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia VEGA-2: Pivotal Phase 3 Trial of Phentolamine Ophthalmic Solution 0.75% in Presbyopia

VEGA-2 Pivotal Phase 3 Trial of Phentolamine Ophthalmic Solution 0.75% in Presbyopia: View Clinical Trial

Completed Trials

Completed

Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330

ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330: View Clinical Trial

Completed

Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis Reversal of Mydriasis Phase 2 Clinical Trial with Phentolamine Ophthalmic Solution 0.75%

Reversal of Mydriasis Phase 2 Clinical Trial with Nyxol: View Clinical Trial

Completed

Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma Phase 2 Clinical Trial of Nyxol in Elderly Subjects with Glaucoma

Phase 2 Clinical Trial of Phentolamine Ophthalmic Solution 0.75% in Elderly Subjects with Glaucoma: View Clinical Trial

Completed

Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances Severe Night Vision Disturbance Single-Dose Phase 2 Clinical Trial with Nyxol

Severe Night Vision Disturbance Single-Dose Phase 2 Clinical Trial with Nyxol: View Clinical Trial

Completed

The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances Night Vision Complaints Multiple-Dose Phase 2 Clinical Trial with Nyxol

Night Vision Complaints Clinical Trial: View Clinical Trial

Completed

A Study of APX3330 in Patients With Advanced Solid Tumors APX3330 Cancer Phase 1 Clinical Trial

APX3330 Cancer Phase 1 Clinical Trial: View Clinical Trial

Completed

Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects MIRA-4: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects

MIRA-4: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects: View Clinical Trial

Completed

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3) MIRA-3: A Phase 3 Clinical Trial Evaluating the Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)

MIRA-3: View Clinical Trial

Completed

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol

MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol: View Clinical Trial

Completed

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol

LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol: View Clinical Trial

Completed

Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine

VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine: View Clinical Trial